{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:04:44Z","timestamp":1789733084578,"version":"4.0.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This study systematically delineates the clinical research status and trends in bladder cancer (Bca) therapeutics through an analysis of 1024 Bca drug treatment clinical trials identified from a harmonised search of the Trialtrove database, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) database as of December 31, 2025. The results demonstrate that the overall number of clinical trials has tended to increase, with a subsequent decline observed in the post-COVID-19 period; the United States has led research efforts, followed by China, the United Kingdom, Canada, and Australia, which together account for 68.6% of all registered trials; the therapeutic focus has shifted from traditional chemotherapy toward immunotherapy (38.4% of trials, primarily targeting PD-1, PD-L1 and ICIs) and targeted therapies [24.7% of trials, e.g., FGFR inhibitors and Nectin-4-targeting antibody\u2013drug conjugates (ADCs)]. Among validated clinical advances, the EV-302 trial established enfortumab vedotin plus pembrolizumab as the first-line standard of care for locally advanced or metastatic urothelial carcinoma. However, the high trial registration frequency does not uniformly translate into clinical benefit, as exemplified by the subsequent withdrawal of atezolizumab\u2019s bladder cancer indications following negative confirmatory phase III results. In the future, molecular subtype-based personalized treatment strategies, including circulating tumor DNA (ctDNA)-guided adjuvant therapy, novel ADC combination strategies, and artificial intelligence (AI)-driven multiomics integration, will be pivotal for enhancing therapeutic outcomes in Bca.<\/jats:p>","DOI":"10.3389\/fonc.2026.1747070","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:29:56Z","timestamp":1789730996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical landscape of bladder cancer treatment: a brief report on new developments and future perspectives in pharmaceutical interventions"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiao","family":"Xu","sequence":"first","affiliation":[{"name":"Research Center of Molecular Medicine (Ph.D. Lab), Nantong Health Vocational College, Nantong Health College of Jiangsu Province","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Hao","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Affiliated Hospital of Nantong University","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Nantong Hospital of Traditional Chinese Medicine","place":["Nantong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: Current challenges and future directions [review","volume":"57","author":"Dobruch","year":"2021","journal-title":"Med (Kaunas)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40779-024-00569-w","article-title":"Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021","volume":"11","author":"Zi","year":"2024","journal-title":"Mil Med Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0000000000000606","article-title":"Quality of life in non-muscle-invasive bladder cancer survivors: A systematic review","volume":"42","author":"Jung","year":"2019","journal-title":"Cancer Nurs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70345","article-title":"Psychological distress in bladder cancer patients: A systematic review","volume":"13","author":"Thomas","year":"2024","journal-title":"Cancer Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1364702","article-title":"The clinical effect of gratitude extension-construction theory nursing program on bladder cancer patients with fear of cancer recurrence","volume":"14","author":"Qian","year":"2024","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/tau-23-494","article-title":"A narrative review of management of muscle-invasive bladder cancer perioperative period: Will continuous and combined treatment be the new trend","volume":"13","author":"Lan","year":"2024","journal-title":"Transl Androl Urol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: A review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907377","article-title":"Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis","volume":"12","author":"Zheng","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00194-23","article-title":"Review of BCG immunotherapy for bladder cancer","volume":"38","author":"Liatsos","year":"2025","journal-title":"Clin Microbiol Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41420-025-02489-7","article-title":"Heightened IDO1 levels predict Bacillus Calmette-Gu\u00e8rin failure in high-risk non-muscle-invasive bladder cancer patients","volume":"11","author":"Turdo","year":"2025","journal-title":"Cell Death Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/tau-22-772","article-title":"Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: Results from a tertiary center in the contemporary BCG-shortage era","volume":"12","author":"Zeng","year":"2023","journal-title":"Transl Androl Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549647","article-title":"Disitamab vedotin vs. gemcitabine-cisplatin regimen with immunotherapy: A comparative analysis of efficacy and safety in muscle-invasive bladder cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6680","article-title":"Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinom","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101055","article-title":"Cancer drug indication approvals in China and the United States: A comparison of approval times and clinical benefit, 2001-2020","volume":"45","author":"Wei","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5581","DOI":"10.1158\/1538-7445.Am2020-5581","article-title":"Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers","volume":"80","author":"Liu","year":"2020","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400156","article-title":"Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer","volume":"11","author":"Ding","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-03209-4","article-title":"World-first therapy using donor cells sends autoimmune diseases into remission","volume":"634","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630569","article-title":"CAR-T cell therapies in autoimmune rheumatic diseases: A brief report on the clinical trial landscape, current status, and future perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01560-y","article-title":"Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning","volume":"8","author":"Bai","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"126399","DOI":"10.1016\/j.jenvman.2025.126399","article-title":"Emerging opportunities or paradoxes: Assessing the effect of digital technology adoption on corporate carbon performance","volume":"391","author":"Lin","year":"2025","journal-title":"Environ Manage"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/su15010006","article-title":"Comparative analysis of machine learning methods and a physical model for shallow landslide risk modeling","volume":"15","author":"Feng","year":"2023","journal-title":"Sustainability"},{"key":"B36","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.47852\/bonviewSWT52025578","article-title":"Wearable technology in healthcare: Opportunities, challenges, and future directions","volume":"1","author":"Qadrie","year":"2025","journal-title":"Smart Wearable Technol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"A13","DOI":"10.47852\/bonviewSWT52026811","article-title":"Switching on smart care: The ascendancy of wireless technologies in continuous health surveillance","volume":"1","author":"Kaur","year":"2025","journal-title":"Smart Wearable Technol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist Update"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3390\/biomedicines11041053","article-title":"Plant-derived exosome-like nanoparticles for biomedical applications and regenerative therapy","volume":"11","author":"Sarasati","year":"2023","journal-title":"Biomedicines"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.5c01547","article-title":"Plant-derived nanovesicles: A promising frontier in tissue repair and antiaging","volume":"73","author":"Zheng","year":"2025","journal-title":"J Agric Food Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"108842","DOI":"10.1016\/j.meatsci.2022.108842","article-title":"Recent trends in the micro-encapsulation of plant-derived compounds and their specific application in meat as antioxidants and antimicrobials","author":"Zhang","year":"2022","journal-title":"Meat Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"104035","DOI":"10.1016\/j.fbio.2024.104035","article-title":"A comprehensive insight into plant-derived extracts\/bioactives: Exploring their antimicrobial mechanisms and potential for high-performance food applications","author":"Rasheed","year":"2024","journal-title":"Food Biosci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1695636","article-title":"Plant-derived extracellular vesicles: An alternative and complementary therapeutic approach for genitourinary tumors","volume":"13","author":"Huang","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058127","article-title":"Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors","volume":"352","author":"De Angelis","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1747070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:29:58Z","timestamp":1789730998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1747070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1747070"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1747070","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1747070"}}